Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2025

Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMengjiao FuChina Agricultural UniversityJQJingjing QuFirst People's Hospital of Yuhang DistrictJZJianya ZhouFirst People's Hospital of Yuhang District

Discussion

Loading...

Member takes

Implication

A retrospective study reports efficacy and safety of various PD-1 inhibitors in advanced squamous NSCLC, suggesting promising outcomes.

Key Points

  • The objective response rate (ORR) reached 48.1% and the disease control rate (DCR) was 87.4% in patients treated with PD-1 inhibitors.
  • Patients treated with pembrolizumab showed the highest ORR of 52.5% with a median overall survival (OS) of 26 months.
  • Immune-related adverse events (irAEs) were experienced by 36% of patients, with nephritis being the most common at 10%.
  • Serum IL-6 levels significantly predicted overall survival, with higher levels correlating to shorter survival (P = 0.021).

Cite This Study

Fu et al. (2025) studied this question.

synapsesocial.com/papers/689a0c7be6551bb0af8d06abhttps://doi.org/10.21203/rs.3.rs-7161891/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis2025 · 2 citations
  2. 2Efficacy and safety of first-line immune checkpoint inhibitors in patients with PD-L1 < 1% metastatic non-small-cell lung cancer – implications for daily clinical practice2025
  3. 3Pembrolizumab in the treatment of non-small cell lung cancer—experiences from clinical practice2025 · 3 citations
  4. 4Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication2025 · 3 citations
  5. 5Real-world efficacy of immune checkpoint inhibitors in PD-L1 negative non-small cell lung cancer: a multicenter retrospective study2025 · 1 citations